SCHEMBL1636562

SCHEMBL1636562

CC(C(=O)O)c1ccc(/N=N/c2ccc(O)c(C(=O)O)c2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.68
KMT2A Q03164 5/20 0.68
BLVRB P30043 2/20 0.68
PDE4A P27815 1/20 0.68
KDR P35968 1/20 0.68
HTT P42858 1/20 0.68
TDP1 Q9NUW8 5/20 0.65
APP P05067 1/20 0.65
THRB P10828 1/20 0.65
RECQL P46063 1/20 0.65
BLM P54132 1/20 0.65
ALDH1A1 P00352 5/20 0.57
PHLPP2 Q6ZVD8 5/20 0.57
HSD17B10 Q99714 3/20 0.57
CYP2C9 P11712 3/20 0.57
PTGS2 P35354 3/20 0.57
CYP2C19 P33261 2/20 0.57
TSHR P16473 2/20 0.57
PTGS1 P23219 1/20 0.57
CYP2D6 P10635 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1636563 1.00 MEN1 (0.68) MEN1KMT2ABLVRBPDE4AKDR
Olsalazine SCHEMBL29378994 0.82 MEN1 (1.00) MEN1KMT2ABLVRBPDE4AKDR
Olsalazine SCHEMBL25119 0.82 MEN1 (1.00) MEN1KMT2ABLVRBPDE4AKDR
Olsalazine SCHEMBL2628413 0.82 MEN1 (1.00) MEN1KMT2ABLVRBPDE4AKDR
Olsalazine SCHEMBL25118 0.82 MEN1 (1.00) MEN1KMT2ABLVRBPDE4AKDR
Olsalazine SCHEMBL29861404 0.82 MEN1 (1.00) MEN1KMT2ABLVRBPDE4AKDR
Olsalazine SCHEMBL29385751 0.82 MEN1 (1.00) MEN1KMT2ABLVRBPDE4AKDR
Olsalazine SCHEMBL2228872 0.81 MEN1 (0.96) MEN1KMT2ABLVRBPDE4AKDR
Olsalazine SCHEMBL29769 0.81 MEN1 (0.96) MEN1KMT2ABLVRBPDE4AKDR
Olsalazine SCHEMBL5922630 0.81 MEN1 (0.96) MEN1KMT2ABLVRBPDE4AKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773767-B1 SYNTHESIS OF AZO BONDED IMMUNOREGULATORY COMPOUNDS BIOCON LTD (IN) 2016-03-09 EP claimed
US-8754197-B2 Synthesis of azo bonded immunoregulatory compounds BIOCON LIMITED (IN) 2014-06-17 US claimed
US-20130096286-A1 SYNTHESIS OF AZO BONDED IMMUNOREGULATORY COMPOUNDS BIOCON LIMITED (IN) 2013-04-18 US claimed
US-8314214-B2 Synthesis of azo bonded immunoregulatory compounds BIOCON LIMITED (IN) 2012-11-20 US claimed
US-20110201792-A1 SYNTHESIS OF AZO BONDED IMMUNOREGULATORY COMPOUNDS BIOCON LIMITED (IN) 2011-08-18 US claimed
US-7932366-B2 Synthesis of azo bonded immunoregulatory compounds BIOCON LIMITED (IN) 2011-04-26 US claimed
US-20080033153-A1 Synthesis of Azo Bonded Immunoregulatory Compounds NOBEX CORPORATION 2008-02-07 US claimed
EP-1773767-A2 SYNTHEIS OF AZO BONDED IMMUNOREGULATORY COMPOUNDS Nobex Corporation (US) 2007-04-18 EP claimed
WO-2006014549-A2 SYNTHESIS OF AZO BONDED IMMUNOREGULATORY COMPOUNDS NOBEX CORPORATION (US) 2006-02-09 WO claimed
US-6583128-B2 Phenylazophenylacetic acid derivatives; treating inflammatory bowel disease NOBEX CORPORATION 2003-06-24 US claimed
EP-1313697-A2 IMMUNOREGULATORY COMPOUNDS, DERIVATIVES THEREOF AND THEIR USE Nobex Corporation (US) 2003-05-28 EP claimed
US-20020049186-A1 Immunoregulatory compounds and derivatives and methods of treating diseases therewith NOBEX CORPORATION 2002-04-25 US claimed
WO-2002018324-A2 IMMUNOREGULATORY COMPOUNDS, DERIVATIVES THEREOF AND THEIR USE NOBEX CORPORATION (US) 2002-03-07 WO claimed
US-8048924-B2 Methods and compositions employing 4-aminophenylacetic acid compounds BIOCON LIMITED (IN) 2011-11-01 US disclosed
US-7425578-B2 Immunoregulatory compounds and derivatives and methods of treating diseases therewith BIOCON LIMITED (IN) 2008-09-16 US disclosed
US-20070060552-A1 Methods and compositions employing 4-aminophenylacetic acid compounds NOBEX CORPORATION 2007-03-15 US disclosed
US-6583128-B2 Phenylazophenylacetic acid derivatives; treating inflammatory bowel disease NOBEX CORPORATION 2003-06-24 US disclosed
EP-1313697-A2 IMMUNOREGULATORY COMPOUNDS, DERIVATIVES THEREOF AND THEIR USE Nobex Corporation (US) 2003-05-28 EP disclosed
US-20020049186-A1 Immunoregulatory compounds and derivatives and methods of treating diseases therewith NOBEX CORPORATION 2002-04-25 US disclosed
WO-2002018324-A2 IMMUNOREGULATORY COMPOUNDS, DERIVATIVES THEREOF AND THEIR USE NOBEX CORPORATION (US) 2002-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096286-A1 SYNTHESIS OF AZO BONDED IMMUNOREGULATORY COMPOUNDS C3AR1, HRH4, FCGRT MEN1 612/4885KMT2A 3091/4885BLVRB 897/4885
US-20070060552-A1 Methods and compositions employing 4-aminophenylacetic acid compounds PGA5, AADAT, ALPI MEN1 4517/4885KMT2A 627/4885BLVRB 3188/4885
US-20110201792-A1 SYNTHESIS OF AZO BONDED IMMUNOREGULATORY COMPOUNDS CBR1, CBR3, HRH4 MEN1 1696/4885KMT2A 2509/4885BLVRB 479/4885
US-20080033153-A1 Synthesis of Azo Bonded Immunoregulatory Compounds HRH4, CBR1, ARG1 MEN1 1541/4885KMT2A 2258/4885BLVRB 475/4885
US-20020049186-A1 Immunoregulatory compounds and derivatives and methods of treating diseases therewith MALT1, CCR1, HRH2 MEN1 2750/4885KMT2A 4092/4885BLVRB 3011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.